sameAs
Therapeutic antibodies, vaccines and antibodyomesCharge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in ratsCertolizumab pegolCanakinumabBispecific antibodies for cancer therapy: the light at the end of the tunnel?RaxibacumabNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originHuman immunoglobulin allotypes: possible implications for immunogenicityOfatumumabUstekinumabDenosumabmAbs: a business perspectiveImmunotoxicity of monoclonal antibodiesPreclinical development of monoclonal antibodies: considerations for the use of non-human primatesIndustrialization of mAb production technology: the bioprocessing industry at a crossroadsTocilizumabRapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell culturesA potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesisSpecific in vivo knockdown of protein function by intrabodiesRituximab: how approval history is reflected by a corresponding patent filing strategyDisulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological functionSeparation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applicationsComparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studiesLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsIn vitro and in vivo modifications of recombinant and human IgG antibodiesBlocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune responseImplementing quality by design for biotech products: Are regulators on track?Drugs derived from phage display: from candidate identification to clinical practiceImplications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesCD19 as an attractive target for antibody-based therapyRegulatory considerations in oncologic biosimilar drug developmentBoosting antibody developability through rational sequence optimization.Monoclonal antibody to dengue capsid protein: its application in dengue studiesStructure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) moleculeGeneration and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgGGeneration, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domainImproving biophysical properties of a bispecific antibody scaffold to aid developabilityStructural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding siteDiscovery and characterization of olokizumab
P1433
Q24599662-4113418E-AE10-433A-884D-DB29BA03568FQ24619854-6BA0EB81-AA3D-4A98-BE7C-F0741CFBF200Q24625401-560B8F93-7FD2-49EF-BA87-684AB81297B6Q24642193-8493917D-8B48-4E24-A8F2-B30F251447D3Q24644083-B27C787F-B13B-4698-845C-E23B6347A3D9Q24644111-6CAEF76A-8FFB-41EF-ABA6-9DDE6F8B3AA5Q24645217-3FB11B2E-57F0-45E3-8835-28F02475AB0CQ24651893-D902A5F1-B88C-44F9-A8A8-46DD9C49C8D7Q24651912-2B65EDA9-5836-4C77-8168-9FA30486BFB9Q24651927-A12D571A-F5D5-46D2-A81E-2268E078616DQ24651938-559AB32B-3F9D-4A78-AC8D-07F92AB072A4Q24653360-FF9D5EE9-B0C6-4E43-9B65-B3FB5CED1C5EQ24653374-A541DA1A-B5C3-4615-BAC0-A2219E795C5EQ24655266-10362355-30A7-4729-BB85-7DDF35BE9C52Q24655304-D1D95DEB-0046-4BD3-A9AA-85BF4B37787EQ24655317-FA84942F-23BF-4185-9605-DA2EE069F1FBQ26700070-83569AE4-ADA9-4345-A7DC-8318883B7236Q26700129-FFD875F8-4C55-4CEF-B71D-F4E76DD82E86Q26801077-417845A4-1EE4-432F-9319-B70D91549F03Q26821872-33C62502-F876-4C28-A669-77E90E0E0344Q26823047-1F71310D-8B89-43A9-B63F-D4C9339E84DDQ26824543-056504C8-D36B-4F16-AD5E-B21FA4DEF6A2Q26830923-620A9D07-DDE7-4B18-BB79-537256B21926Q26849243-88E3C898-6BD6-4515-91BC-CAB2D8BC23FAQ26852287-48D37AEF-A4FB-4EF6-9BA6-33E44D19F83FQ26859713-D848C728-2BE6-4B0F-9C56-2774D0DB77DEQ26863081-2DEB289B-278B-444C-A2C0-57275B13E528Q26865372-FC8D229C-3FC2-4F22-9CC4-7575D81DDF65Q27007101-D2F14946-4FCA-4053-8E9A-434E0E5AB7DFQ27007486-59138E17-5073-49C2-A8FB-6226183BA26BQ27011836-74B73212-15E1-4581-80D2-EBDC5E83BB07Q27027947-ABE6BE55-63A8-4BE0-9D25-127F597237C0Q27311159-78CF1A2C-E4E5-43D0-8DD9-6549C5597D57Q27489123-4C6E372C-48CE-430E-A492-74ADFFC65365Q27677183-4D6A90E7-0EA4-49C8-9912-B81AB626B364Q27678647-F6FB4C92-CF76-494E-BAF7-411FEAEE4071Q27679386-5D38119D-9E15-4A52-AE0B-0E313B96D640Q27679445-E3DCD305-E472-49B3-AE00-77A1EDB5D12CQ27681324-658C0E5A-3B13-4FBB-A477-E04240A14C18Q27682535-46357B5F-385D-49BC-8663-3C9E4929976D
P1433
description
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
scientific journal
@en
vědecký časopis
@cs
wetenschappelijk tijdschrift van Landes Bioscience
@nl
wissenschaftliche Fachzeitschrift
@de
науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Monoclonal Antibodies
@ast
Monoclonal Antibodies
@de
Monoclonal Antibodies
@en
Monoclonal Antibodies
@es
Monoclonal Antibodies
@fr
Monoclonal Antibodies
@it
Monoclonal Antibodies
@nl
type
label
Monoclonal Antibodies
@ast
Monoclonal Antibodies
@de
Monoclonal Antibodies
@en
Monoclonal Antibodies
@es
Monoclonal Antibodies
@fr
Monoclonal Antibodies
@it
Monoclonal Antibodies
@nl
altLabel
mAbs
@en
mAbs
@nl
prefLabel
Monoclonal Antibodies
@ast
Monoclonal Antibodies
@de
Monoclonal Antibodies
@en
Monoclonal Antibodies
@es
Monoclonal Antibodies
@fr
Monoclonal Antibodies
@it
Monoclonal Antibodies
@nl
P243
P3181
P4616
P1055
P1144
2008215188
P1156
19700168103
P1277
P1476
Monoclonal Antibodies
@en
P236
P243
P3181
P407
P571
2009-01-01T00:00:00Z